1. Repositorio institucional UNIMINUTO
  2. Trabajos de Grado
  3. Universitarios
  4. Psicología
Please use this identifier to cite or link to this item: https://repository.uniminuto.edu/handle/10656/5973
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGómez Suárez, Oscar Alejandro
dc.contributor.authorCastañeda Ibáñez, Nolly Nataly; Asesor
dc.coverage.spatialBogotá D.C.es_ES
dc.date.accessioned2018-04-23T21:08:47Z
dc.date.available2018-04-23T21:08:47Z
dc.date.issued2017
dc.identifier.citationGómez,O. (2017).Evaluación neuropsicológica de un adulto con la enfermedad de Fabry en la ciudad de Bogotá, Colombia: estudio de caso. (Trabajo de grado). Corporación Universitaria Minuto de Dios, Bogotá-Colombia.SPA
dc.identifier.urihttp://hdl.handle.net/10656/5973
dc.description.abstractLa Enfermedad Fabry, hace parte de las enfermedades de depósito lisosomal, que se clasifica dentro de los errores innatos del metabolismo, que es hereditaria y se encuentra ligada genéticamente al cromosoma X. Se caracteriza por la deficiencia de la enzima Alfa-galactosidasa A en las células, lo que dificulta la degradación del lípido denominado Globotriaosilceramida (GB3), lo que provoca su acumulación en la mayoría de los tejidos y órganos del cuerpo. Igualmente se encuentran manifestaciones a nivel neurocognitivo las cuales son heterogéneas, por lo cual el objetivo del presente estudio es determinar las características neuropsicológicas de un adulto masculino con la Enfermedad Fabry en Bogotá, Colombia, mediante la realización de un estudio de caso.en
dc.language.isoesen
dc.publisherCorporación Universitaria Minuto de Diosen
dc.subjectEnfermedadesen
dc.subjectCaracterísticas Neuropsicológicasen
dc.subjectEnfermedad de Fabryen
dc.subjectNeuropsicologíaen
dc.titleEvaluación neuropsicológica de un adulto con la enfermedad de Fabry en la ciudad de Bogotá, Colombia: estudio de caso.en
dc.typeThesisen
dc.subject.lembNeuropsicologíaes
dc.subject.lembCiencia cognoscitivaes
dc.subject.lembCienciaes
dc.subject.lembPsicología Cognoscitivaes
dc.publisher.programPsicologíaes_ES
dc.source.bibliographicCitationAguirre, E., Woods, R., Spector, A., & Orrell, M. (2013). Cognitive stimulation for dementia: A systematic review of the evidence of effectiveness from randomised controlled trials. Ageing Research Reviews, 12(1), 253-262. doi:10.1016/j.arr.2012.07.001
dc.source.bibliographicCitationAlfadhel, M. & Sirris, S. (2011). Enzyme replacement therapy for Fabry disease: some answers but more questions. Therapeutics and Clinical Risk Management, 7, 69-82.
dc.source.bibliographicCitationAltarescu, G., Haim, S. & Elstein, D. (2013). Angiotensinogen promoter and angiotensinogen II receptor type 1 gene polymorphisms and incidence of ischémie stroke and neurologic phenotype in Fabry disease. Biomakers, 18 (7), 595-600.
dc.source.bibliographicCitationArango, L. J., & Rivera, D. (2015). Neuropsicología en Colombia: Datos normativos, estado actual y retos a futuro.
dc.source.bibliographicCitationArends, M., Wanner, C., Hughes, D., Mehta, A., Oder, D., Watkinson, O., Elliott, P., Linthorst, G., Wijburg, F., Biegstraaten, M. & Hollak, C. (2016). Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study.Journal of the American Society of Nephrology. doi:10.1681/asn.2016090964
dc.source.bibliographicCitationAssareh, A., Mather, K. A., Schofield, P. R., Kwok, J. B., & Sachdev, P. S. (2010). The Genetics of White Matter Lesions. CNS Neuroscience & Therapeutics, 17(5), 525-540. doi:10.1111/j.1755-5949.2010.00181.x
dc.source.bibliographicCitationAzancot, M., Vila, J., Domínguez, C., Serres, X. y Espinel, E. (2016). Múltiples quistes parapiélicos en la enfermedad de Fabry. Neufrología. 36 (3), 310-312.
dc.source.bibliographicCitationBangari, D., Ashe, k., Desnick, R., Maloney, C., Lydon, J., Piepenhagen, P., Budman, E., Leonard, J. Cheng, S., Marshall, J. & Thurberg, B. (2015). a-Galactosidase A Knockout Mice Progressive Organ Pathology Resembles the Type 2 Later-Onset Phenotype of Fabry Disease. The American Journal of Pathology, 185 (3), 651-665. doi.org/10.1016/j.ajpath.2014.11.004
dc.source.bibliographicCitationBersano, A., Lanfranconi, S., Valcarenghi, C., Bresolin, N., Micieli, G., & Baron, P. (2012). Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy. Acta Neurologica Scandinavica, 126(2), 77-97. doi:10.1111/j.1600- 0404.2012.01661.x
dc.source.bibliographicCitationBobillo, J., Jiménez, M. y Jiménez, L. (2016), Biomarkers in Lysosomal Storage Diseases. Diseases, recuperado de http://www.mdpi.com/2079-9721/4/4/40
dc.source.bibliographicCitationBolsover, F., Murphy, E., Cipolotti, L., Werring, D. & Lachmann, R. (2014). Cognitive dysfunction and depression in Fabry disease: a systematic review. Journal of Inherited Metabolic Disease, 37(2), 177-187. doi:10.1007/s10545-013-9643-x
dc.source.bibliographicCitationBurlina, A., Sims, K., Politei, J., Bennett, G., Baron, R., Sommer, C., Torvin, A. & Hilz, M. (2011). Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurology, 11 (61), recuperado de http://bmcneurol.biomedcentral.com/articles/10.1186/1471-2377-11-61
dc.source.bibliographicCitationCamargo, J. y Cantillo, J. (2009). Enfermedad de Fabry Una perspectiva histórica desde la semiología dermatológica hasta la correlación genética. Acta médica colombiana, 34 (3), 140-151.
dc.source.bibliographicCitationChillon, J., Brazier, F., Bouquet, P., & Massy, Z. (2014). Neurological Disorders in a Murine Model of Chronic Renal Failure. Toxins, 6(1), 180-193. doi:10.3390/toxins6010180
dc.source.bibliographicCitationChoi, L., Vernon, J., kopach, O., Minett, M., Mills, K., Clayton, P., Meert, T. & Wood, J. (2015). The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain. Neuroscience Letters, 594, 163-168. doi:10.1016/j.neulet.2015.01.084
dc.source.bibliographicCitationCongreso de Colombia. (2010). LEY 1392 DE 2010. (Secretaría General de la Alcaldía Mayor De Bogotá D.C.). Recuperado de: http://www.alcaldiabogota.gov.co/sisjur/normas/Norma1.jsp?i=39965
dc.source.bibliographicCitationCongreso de Colombia. (2011). Ley 1438 DE 2011. (Secretaría General de la Alcaldía Mayor De Bogotá D.C.). Recuperado de: http://www.alcaldiabogota.gov.co/sisjur/normas/Norma1.jsp?i=41355#140
dc.source.bibliographicCitationCruz, C., Olivares, O., & González, G. (2014). Metodología de la investigación. Mexico: Grupo Editorial Patria.
dc.source.bibliographicCitationDaghfous, A., Toledano, E., Kalsoum, E., Tempremant, F., Boulanger, T., Leclerc, X. & Pruvo, J. (2015). Fabry disease. Diagnostic and Interventional Imaging, 96(3), 307-309. doi:10.1016/j.diii.2014.02.021
dc.source.bibliographicCitationDavey, P. (2014). Fabry disease: a survey of visual and ocular symptoms. Clinical Ophthalmology, 8, 1555-1560. doi:10.2147/opth.s66748
dc.source.bibliographicCitationDucuara, D. y Saravia, I. (2015). Prevalencia de enfermedad de Fabry en pacientes en lista de trasplante y post- trasplante renal en fundación Cardioinfantil Bogotá (Tesis de posgrado). Universidad del Rosario, Bogotá, Colombia.
dc.source.bibliographicCitationElstein, D., Doniger, G., Simon, E., & Altarescu, G. (2010). Computerized cognitive testing in patients with Fabry disease: A descriptive pilot study. Molecular Genetics and Metabolism,99(2), S17-S18. doi:10.1016/j.ymgme.2009.10.064
dc.source.bibliographicCitationFukutomi, M., Tanaka, N., Uchinoumi, H., Kanemoto, M., Nakao, F., Yamada, J.… Fujii, T. (2013). Japanese patients with Fabry disease predominantly showing cardiac and neurological manifestation with novel missense mutation: R220P. Journal of Cardiology, 62(1), 63-69. doi:10.1016/j.jjcc.2013.02.012
dc.source.bibliographicCitationGairing, S., Wiest, R., Metzler, S., Theodoridou, A., & Hoff, P. (2011). Fabry’s Disease and Psychosis: Causality or Coincidence? Psychopathology, 44(3), 201-204. doi:10.1159/000322794
dc.source.bibliographicCitationGalvis, W., Santacoloma, G. y Jaramillo, F. (2014). Enfermedad de Fabry. Revista de la asociación colombiana de Dermatología y cirugía dermatológica, 22(1), 81- 85.
dc.source.bibliographicCitationGarcía, L. (2011). Consenso para el estudio y tratamiento de la enfermedad de Fabry. Fundación GETER. Med Clin (Barc), 137(4):178–183. doi:10.1016/j.medcli.2011.02.024
dc.source.bibliographicCitationGermain, D. (2010). Fabry disease. Orphanet Journal of Rare Diseases, 5, 30. http://doi.org/10.1186/1750-1172-5-30
dc.source.bibliographicCitationGermain, D., Hughes, D., Nicholls, K.., Bichet, D., Giugliani, R., Wilcox, W., Feliciani, C…. Schiffmann, R. (2016). Treatment of Fabry Disease with the Pharmacological Chaperone Migalastat. The New England Journal of Medicine, 375 (6), 545-555.
dc.source.bibliographicCitationGonzález C., Arenas, C. y Jaimes, A. (2013). Enfermedad de Fabry. Diagnóstico dermatológico temprano y tratamiento. Piel, 28(3), 134-136. doi:10.1016/j.piel.2012.08.002
dc.source.bibliographicCitationGuerrero, G. (2014). Metodología de la Investigación (1st ed.). México D.F.: Grupo Editorial Patria
dc.source.bibliographicCitationHebben, N., Milberg, W. (2011). Fundamentos para la evaluación neuropsicológica. (Veléz, G. Trad.). México: Editorial Manual Moderno (Trabajo original publicado en el 2009)
dc.source.bibliographicCitationHernández, R., Fernández C. y Baptista, P. (2010). Metodología de la investigación (5ta edición). México DF, México: McGra-Whill Interamericana Editores S.A.
dc.source.bibliographicCitationHerrera, J. (2008). Enfermedad de Fabry: una forma de enfermedad renal crónica diagnosticable y tratable. Nefrología, 28 (8), 13- 19.
dc.source.bibliographicCitationHossain, M., Yanagisawa, H., Miyajima, T., Wu, C., Takamura, A., Akiyama, K., Itagaki, R., Eto, K, Iwamoto, T., Yokoi, T., Kurosawa, K., Numabe, H. & Eto, Y. (2017). The severe clinical phenotype for a heterozygous Fabry female patient correlates to the methylation of non-mutated allele associated with chromosome 10q26 deletion syndrome.Molecular Genetics and Metabolism, 120(3), 173-179. doi:10.1016/j.ymgme.2017.01.002
dc.source.bibliographicCitationHsu, T., Hung, S., Chang, Fu, Yu, W., Sung, S., Hsu, S., Dzhagalov, I., Yang, C., Chu, T., Lee, H., Lu, Y., Chang, S., Liao, H., Lin, H., Liao, T., Lee, P., Li, H., Yang, A., Ho, H. Chiang, C., Lin, C., Desnick, R. & Niu, D. (2016). Later onset Fabry Disease, cardiac damage progress in silence. Journal of American College of Cardiology, 68 (23), 2554- 2563.
dc.source.bibliographicCitationJain, G. & Warnock, D. (2011). Blood pressure, Proteinuria and Nephropathy in Fabry Disease. Nephron Clinical Practice, 118, 43-48.
dc.source.bibliographicCitationJudge, D., Okwousa, I. & Hagège, A. (2016). GLA-Ring Opportunities and Challenges for Fabry Disease. Journal of the American College of Cardiology, 68 (23), 2264-2566.
dc.source.bibliographicCitationJuliao, C. (2011). El enfoque praxeológico (1st ed.). Bogotá, Colombia: Corporación Universitaria Minuto de Dios – Uniminuto.
dc.source.bibliographicCitationKaneski, C., Brady, R., Hanover, J. & Schueler, U. (2016). Development of a model system for neuronal dysfunction in Fabry disease. Molecular Genetics and Metabolism, 119, 144- 150
dc.source.bibliographicCitationKobayashi, M., Ohashi, T., Iizuka, S., Kaneshiro, E., Higuchi, T., Eto, Y., & Ida, H. (2014). Frequency of de novo mutations in Japanese patients with Fabry disease. Molecular Genetics and Metabolism Reports, 1, 283-287. doi:10.1016/j.ymgmr.2014.07.001
dc.source.bibliographicCitationKusano, E., Saito, O., Akimoto, T. & Asano, Y.(2014). Fabry disease: experience of screening dialysis patients for Fabry disease. Clinical and Experimental Nephrology, 269-273.
dc.source.bibliographicCitationKubo, T., Ochi, Y., Baba, Y., Hirota, T., Tanioka, K., Yamasaki, N., Yoshimitsu, M., Higuchi, K., Toshihiro, T., Nakajima, K., Togawa, T., Tsukimura, T., Sano, S., Tei, C., Sakuraba, H. & Kitaoka, H. (2017). Prevalence and clinical features of Fabry disease in Japanese male patients with diagnosis of hypertrophic cardiomyopathy. Journal of Cardiology, 69(1), 302-307. doi:10.1016/j.jjcc.2016.05.014
dc.source.bibliographicCitationLakomá, J., Donadio, V., Liguori, R., & Caprini, M. (2015). Characterization of Human Dermal Fibroblasts in Fabry Disease. Journal of Cellular Physiology, 231(1), 192-203. doi:10.1002/jcp.25072
dc.source.bibliographicCitationLaney, D., Gruskin, D., Fernhoff, P., Ousley, O., Hipp, H. & Mehta, A. (2010). Social-Adaptive and psychological functioning of patients affected by Fabry disease. Journal of Inheredit Metabolism Diseases, 33, 73-81
dc.source.bibliographicCitationLelieveld, I., Böttcher, A., Hennermann, J., Beck, M., & Fellgiebel, A. (2015). Eight-Year Follow-Up of Neuropsychiatric Symptoms and Brain Structural Changes in Fabry Disease. PLOS ONE, 10(9), e0137603. doi:10.1371/journal.pone.0137603
dc.source.bibliographicCitationLey N. 1090. Diario Oficial No. 46.383 de la Republica de Colombia. Congreso de Colombia, 6 de Septiembre del 2006
dc.source.bibliographicCitationLin, H.-Y., Liu, H.-C., Huang, Y.-H., Liao, H.-C., Hsu, T.-R., Shen, C.-I., … Niu, D.-M. (2013). Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A). BMJ Open, 3(7), e003146. http://doi.org/10.1136/bmjopen-2013-003146
dc.source.bibliographicCitationLidove, O., Barbey, F., Niu, D., Brand, E., Nicholls, K., Bizjajeva, S., & Hughes, D. (2016). Fabry in the older patient: Clinical consequences and possibilities for treatment. Molecular Genetics and Metabolism, 118(4), 319-325. doi:10.1016/j.ymgme.2016.05.009
dc.source.bibliographicCitationLidove, O., Jaussaud, R. & Aractingi, S. (2006) Dermatological and soft-tissue manifestations of Fabry disease: characteristics and response to enzyme replacement therapy. En A. Mehta, M. Beck & G. Sunder-Plassmann (ED.), Fabry Disease: Perspectives from 5 Years of FOS (Capitulo 24). Oxford: Oxford PharmaGenesis. Recuperado en https://www.ncbi.nlm.nih.gov/books/NBK11605/
dc.source.bibliographicCitationLópez-Bastida, J., Oliva-Moreno, J., Linertová, R., & Serrano-Aguilar, P. (2016). Social/economic costs and health-related quality of life in patients with rare diseases in Europe. The European Journal of Health Economics, 17(S1), 1-5. doi:10.1007/s10198- 016-0780-7
dc.source.bibliographicCitationMarek, R., Cooklin, M., Carr-White, G., & O’Neill, M. (2016). Atrial Tachycardia in a Patient with Fabry’s Disease. HeartRhythm Case Reports, 2(2), 124-127. doi:10.1016/j.hrcr.2015.10.007
dc.source.bibliographicCitationMolina, A. (2017). Anomalías Vasculares. En Amaya, P., Chávez, A. y Robledo, S. (Coordinadores). Primera Jornada de Actualización en Enfermedades Huérfanas. Ministerio de Salud y Protección Social – Universidad Nacional de Colombia, Bogotá, Colombia.
dc.source.bibliographicCitationNaaman, R. (2013). Lysosomal storage diseases-the horizon expands. Nature Reviews, 9, 583- 598.
dc.source.bibliographicCitationNagano, T., Nakatsuka, S., Fujita, S., Kanda, T., Uematsu, M., Ikeda, Y., Ishabashi, H. & Yutani, C. (2016). Myocardial fibrosis pathology in Anderson–Fabry disease: Evaluation of autopsy cases in the long- and short-term enzyme replacement therapy, and non-therapy case. IJC Metabolic & Endocrine, 12, 46-51. doi:10.1016/j.ijcme.2016.06.002
dc.source.bibliographicCitationNageswaramma, S., Swarna, G., Rajashekar, P., Sowmya, S. & Sirisha, G. (2015). Angiokeratoma Corporis Diffusum - A case report. Journal of Dental and Medical Sciences, 14 (1), 11-13.
dc.source.bibliographicCitationNational Kidney Foundation. (2016). Clinical update Fabry Disease and Chronic Kidney Disease. Retrieved from https://www.kidney.org/sites/default/files/02-10-7244_CBGFabry_Bulletin-5b.pdf
dc.source.bibliographicCitationNiemann, M., Herrmann, S., Hu, K., Breunig, F., Strotmann, J., Beer, M., Machann, W., Voelker, W., Ertl, G., Wanner, F. & Weidemann, F. (2011). Differences in Fabry Cardiomyopathy Between Female and Male Patients. JACC: Cardiovascular Imaging, 4(6), 592-601. doi:10.1016/j.jcmg.2011.01.020
dc.source.bibliographicCitationNowak, A., Mechtler, T., Desnick, R. & Kasper, D. (2017). Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes. Molecular genetics and Metabolism, 120, 57-61.
dc.source.bibliographicCitationOrtiz, A., Abiose, A., Bichet, D., Cabrera, G., Charrow, J., Germain, D., Hopkin, R., Jovanovic, A., Linhart, A. Maruti, S., Mauer, M., Oliveira, J., Patel, M., Politeli, J., Waldek, S., Wanner, C., Yoo, H. & Warnock, D. (2016). Time to treatment benefit for adults patients with Fabry disease receiving agalsidase β: Data from the Fabry Registry. Journal of Medical Genetics, 53, 495-502.
dc.source.bibliographicCitationPatel, M. R., Cecchi, F., Cizmarik, M., Kantola, I., Linhart, A., Nicholls, K., Strongman, J., Tallaj, J., Chien, T., West, M., Beitner, D. & Abiose, A. (2010). Cardiovascular events in patients with fabry disease: natural history data from the fabry registry. Journal of the American College of Cardiology, 55(10), 1093-1099. doi:10.1016/s0735-1097(10)60292- 6
dc.source.bibliographicCitationPeña-Casanova, J. (2005) Programa Integrado de Exploración Neuropsicológica. Test Barcelona Revisado. Barcelona: Masson
dc.source.bibliographicCitationPinto, L., Vieira, T., Giugliani, R. & Schwartz, I. (2010). Expression of the disease on female carriers of X-linked lysosomal disorders: a brief review. Orphanet Journal of Rare Diseases, 5(14). DOI: 10.1186/1750-1172-5-14
dc.source.bibliographicCitationPinto, D., Parra, O. y Verano, R. (2008). La carga económica de la enfermedad de Gaucher y Fabry en Colombia. Implicaciones para el Sistema General de Seguridad social en Salud de dos enfermedades de alto costo. FEDESAROLLO. Recuperado de http://hdl.handle.net/11445/1009
dc.source.bibliographicCitationPisani, A., Riccio, E. & Sabbatini, M. (2015). Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?. American College of Medical Genetics and Genomics, 17 (1), 21-23
dc.source.bibliographicCitationPolitei, J. M., Bouhassira, D., Germain, D. P., Goizet, C., Guerrero‐Sola, A., Hilz, M. J., Burlina, A. et. al. (2016). Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment. CNS Neuroscience & Therapeutics, 22(7), 568–576. http://doi.org/10.1111/cns.12542
dc.source.bibliographicCitationPlatt, F., Boland, B. & Van der Spoel, A. (2012). Lysosomal storage disorders: The cellular impact of lysosomal dysfunction. The Journal of Cell Biology, 199 (5), 723-734.
dc.source.bibliographicCitationRazza, G., Spadaro, D., Giordano, A., Scalia, S., Colomba, P., Zizzo, C.,… Iemolo, F. (2016). Cognitive impairment and Fabry Disease: a case report with mutation S126G.Neuropsychological Trends, (20), 173-185. doi:10.7358/neur-2016-020-razz
dc.source.bibliographicCitationRob, D., Marek, J., Dostálová, G., Golán, L. & Linhart, A. (2016). Uric Acic as a Maker of Mortality and Morbidity in Fabry Disease. PLoS ONE, 11 (11), 1-13. recuperado de http://dx.doi.org/10.1371/journal.pone.0166290
dc.source.bibliographicCitationRosas, R., Tenorio, M., Pizarro, M., Cumsille, P., Bosch, A., & Zapata-Sepúlveda, P. (2014). Estandarización de la Escala Wechsler de Inteligencia Para Adultos-Cuarta Edición en Chile [Tabla]. Psykhe (Santiago), 23(1), 1-18. doi:10.7764/psykhe.23.1.529
dc.source.bibliographicCitationSánchez, M., Gálvez, S., Ortiz, P., y López, A. (2010). Paciente afecta de enfermedad de Fabry. Revista de la Sociedad Española de Enfermería Nefrológica, 13(1), 82-85. Recuperado de http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S113913752010000100009&lng =es&tlng=es
dc.source.bibliographicCitationSchermuly, I., Müller, M., Müller, K., Albrecht, J., Keller, I., Yakushev, I., Beck, M. & Fellgiebel, A. (2011). Neuropsychiatric symptoms and brain structural alterations in Fabry disease. European Journal of Neurology, 18, 347-353.
dc.source.bibliographicCitationSchiffmann, R., Hughes, D., Linthorst, G., Ortiz, A., Svarstad, E., Warnock, D., West, M. & Wanner, C. (2017). Screening, diagnosis, and management of patients with Fabry disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney International, 91, 284-293.
dc.source.bibliographicCitationSegal, P., Kohn, Y., Pollak, Y., Altarescu, G., Galili-Weisstub, E., & Raas-Rothschild, A. (2010). Psychiatric and cognitive profile in Anderson-Fabry patients: a preliminary study. Journal of Inherited Metabolic Disease, 33(4), 429-436. doi:10.1007/s10545-010-9133-3
dc.source.bibliographicCitationShi, Q., Chen, J., Pongmoragot, J.& Saposnik, G. (2013). Prevalence of Fabry Disease in Stroke Patients -A Systematic Review and Meta-analysis. Journal of stroke and cerebrovascular diseases: the official journal of National Stroke Association, 23 (5), 1-8. doi: http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2013.08.010
dc.source.bibliographicCitationSerebrinsky, G., Calvo, M., Fernandez, S., Saito, S., Ohno, K., Wallace, E., Politei, J. (2015). Late onset variants in Fabry disease: Results in high-risk population screenings in Argentina.Molecular Genetics and Metabolism Reports, 4, 19-24. doi:10.1016/j.ymgmr.2015.05.006
dc.source.bibliographicCitationSigmundsdottir, L., Tchan, M., Knopman, A. Menzies, G., Batchelor, J. & Sillence, D. (2014). Cognitive and Psychological Functioning in Fabry Disease. Archives of Clinical Neuropsychology 29, 642–650. doi:10.1093/arclin/acu047
dc.source.bibliographicCitationSilva, J., Rochford, L., Hopkin, R. & Jefferies, J. (2016). Ventricular Tachycardia in Fabry Disease. Texas Heart Institute Journal, 43 (6), 531-533.
dc.source.bibliographicCitationSmid, B., Van der Tol, L., Cecchi, F., Elliott, P., Hughes, D., Linthorst, G., Timmermans, J., Weidemann. F., West, M., Biegstraaten, M., Lekanee, R., Florquin, S., Postema, P., Tomberli, M., van der Wal, A., van der Bergh, M. & Hollak, C. (2014). Uncertain diagnosis of Fabry disease: Consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. International Journal of Cardiology, 177(2), 400-408. doi:10.1016/j.ijcard.2014.09.001
dc.source.bibliographicCitationSoto, A., Díaz, R., De los Ríos, D.y García, G. (2010). Enfermedad de Fabry: Evento vascular cerebral en un joven y su abordaje diagnóstico. Revista Mexicana de Neurociencia, 11 (5), 359-362.
dc.source.bibliographicCitationSuzuki, Y. (2013). Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease. Brain and Development, 35(6), 515-523. doi:10.1016/j.braindev.2012.12.002
dc.source.bibliographicCitationTamayo, F., Casals-Coll, M., Sánchez-Benavides, G., Quintana, M., Manero, R., Rognoni, T., Peña-Casanova, J. (2012). Estudios normativos españoles en población adulta joven (Proyecto NEURONORMA jóvenes): normas para las pruebas span verbal, span visuoespacial, Letter-Number Sequencing, Trail Making Test y Symbol Digit Modalities Test. Neurología, 27(6), 319-329. doi:10.1016/j.nrl.2011.12.020
dc.source.bibliographicCitationThimmaiah, R., Murthy, K., & Pinto, D. (2012). Cognitive dysfunction in patients with renal failure requiring hemodialysis. Indian Journal of Psychological Medicine, 34(3), 237. doi:10.4103/0253-7176.106019
dc.source.bibliographicCitationTuttolomondo, A., Pecoraro, R., Simonetta, I., Miceli, S., Pinto, A., & Licata, G. (2013). Anderson-Fabry Disease: A Multiorgan Disease. Current Pharmaceutical Design, 19(33), 5974-5996. doi:10.2174/13816128113199990352
dc.source.bibliographicCitationUnderhill, H., Golden-Grant, K., Garrett, L., Uhrich, S., Zielinski, B., & Scott, C. (2015). Detecting the effects of Fabry disease in the adult human brain with diffusion tensor imaging and fast bound-pool fraction imaging. Journal of Magnetic Resonance Imaging, 42(6), 1611-1622. doi:10.1002/jmri.24952
dc.source.bibliographicCitationUribe, A., Mateus, H., Prieto, J., Palacios, M., Ospina, S., Pasqualim, G., Silveira, U. y Giugligani, R. (2015). Identification of mutations in Colombian patients affected with Fabry disease. Gene, 574, 325-329. doi: http://dx.doi.org/10.1016/j.gene.2015.08.018
dc.source.bibliographicCitationVaras, C., Gómez, G., Morales, M., Molt, F., Cabello, J., Alcántara, A., … Peredo, P. (2012). Guía clínica: consenso para Chile en enfermedad de Fabry. Revista chilena de neuropsiquiatría, 50(3), 191-201. doi:10.4067/s0717-92272012000300009
dc.source.bibliographicCitationVega, O., Pérez, A., & Correa, R. (2011). La enfermedad de Fabry-Anderson: estado actual del conocimiento. Revista de Investigación Clínica, 63(3), 314-321.
dc.source.bibliographicCitationVillalobos, J., Politei, J., Martins, A., Cabrera, G., Amartino, H., Lemay, R., Ospina, S., Suárez, S. y Varas, C. (2012). Fabry Disease in Latin America: Data from the Fabry Registry. Journal of Inherited Metabolic Disease, 165, 91-99.
dc.source.bibliographicCitationWaldek, S., & Feriozzi, S. (2014). Fabry nephropathy: a review – how can we optimize the management of Fabry nephropathy? BMC Nephrology, 15, 72. http://doi.org/10.1186/1471-2369-15-72
dc.source.bibliographicCitationWaldek, S., Patel, M., Banikazemi, M., Lemay, R., & Lee, P. (2009). Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry Registry. Genetics in Medicine, 11(11), 790-796. doi:10.1097/gim.0b013e3181bb05bb
dc.source.bibliographicCitationWechsler, D. (2014), Escala Wechsler de Inteligencia para Adultos IV (WAIS-IV). 3ra edición. Editorial Manual Moderno. ISBN 978- 607- 448- 355-0
dc.source.bibliographicCitationWu, C., Lu, Y., Lu, C., & Wu, C. (2015). Familial angiokeratoma corporis diffusum without identified enzyme defect. Indian Journal of Dermatology, Venereology, and Leprology, 81(1), 46. doi:10.4103/0378-6323.148568
dc.source.bibliographicCitationYates, L., Orgeta, V., Leung, P., Spector, A., & Orrell, M. (2016). Field-testing phase of the development of individual cognitive stimulation therapy (iCST) for dementia. BMC Health Services Research, 16(1). doi:10.1186/s12913-016-1499-y
Appears in Collections:Psicología

Files in This Item:
File Description SizeFormat 
TP_GomezSuarezOscarAlejandro_2017.pdf843.95 kBAdobe PDFThumbnail
View/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.